Search Results

Werewolf Therapeutics, Inc. announced new clinical data from the Phase 1/1b trial evaluating WTX-124, its conditionally activated Interleukin-2 INDUKINETM molecule, in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy.

Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement.

Werewolf Therapeutics, Inc. announced that an abstract providing an update of the Company’s ongoing monotherapy and combination Phase 1/1b study of WTX-124, its interleukin 2 INDUKINE™ molecule, has been accepted for poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 - June 4 in Chicago, Illinois.

Everest Medicines announced that the Company expects to record a total revenue ranging between RMB124 million and RMB126 million for 2023, according to preliminary review of unaudited management accounts.

Werewolf Therapeutics, Inc. announced the upcoming presentation of clinical data from dose-escalation arms of the Phase 1/1b trial evaluating WTX-124, its conditionally activated Interleukin-2 INDUKINE™ molecule, as monotherapy and in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy.

Orexo AB, announces the New Drug Application for OX124 has been accepted for review by the US Food and Drug Administration.